These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 8170820

  • 21. [Lipolytic activity of kidney tissue in experimental nephrotic syndrome].
    Leĭtes SM, Nikiforova NV.
    Vopr Med Khim; 1967; 13(4):404-8. PubMed ID: 5598540
    [No Abstract] [Full Text] [Related]

  • 22. Study of hyperlipidemia in adults with nephrotic syndrome.
    Khanna UB, Nerurkar SV, Almeida AF, Taskar SP, Acharya VN.
    J Postgrad Med; 1985 Jul; 31(3):140-5. PubMed ID: 4087215
    [No Abstract] [Full Text] [Related]

  • 23. [Lipid metabolism in kidney diseases].
    Yoshitoshi Y, Naito C.
    Naika; 1968 Oct; 22(4):824-30. PubMed ID: 4884620
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Complications of the nephrotic syndrome and their treatment.
    Crew RJ, Radhakrishnan J, Appel G.
    Clin Nephrol; 2004 Oct; 62(4):245-59. PubMed ID: 15524054
    [Abstract] [Full Text] [Related]

  • 26. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome.
    Büyükçelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, Aydingülü H, Dikmen N.
    Turk J Pediatr; 2002 Oct; 44(1):40-4. PubMed ID: 11858378
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
    Shafrir E.
    Isr J Med Sci; 1996 Jun; 32(6):390-7. PubMed ID: 8682644
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Treatment of hyperlipidemia in nephrotic syndrome: time for a change?
    Olbricht CJ, Koch KM.
    Nephron; 1992 Jun; 62(2):125-9. PubMed ID: 1436302
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ischaemic heart disease, lipids and the kidney.
    Brown JH, Short CD, Mallick NP.
    Contrib Nephrol; 1993 Jun; 102():198-219. PubMed ID: 8416183
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Dyslipidemia in pediatric nephrotic syndrome: causes revisited.
    Delvin EE, Merouani A, Levy E.
    Clin Biochem; 2003 Mar; 36(2):95-101. PubMed ID: 12633757
    [No Abstract] [Full Text] [Related]

  • 36. [The edemas. Nephrotic syndrome].
    Tielemans C.
    Rev Med Brux; 2000 Jun; 21(3):A178-80. PubMed ID: 10925601
    [No Abstract] [Full Text] [Related]

  • 37. [Therapeutic management].
    Vanzetto G, Fouque D, Moulin B, Halimi S, Kessler M, Bayle F.
    Nephrologie; 2000 Jun; 21(7):383-92. PubMed ID: 11200619
    [No Abstract] [Full Text] [Related]

  • 38. [Lipid disturbances in the nephrotic syndrome].
    Chmielewski M, Zdrojewski Z, Rutkowski B.
    Przegl Lek; 2003 Jun; 60(11):758-61. PubMed ID: 15058052
    [Abstract] [Full Text] [Related]

  • 39. Estimation of the phospholipid phosphorus turnover time in man: studies in normal individuals, in patients with the nephrotic syndrome and in other types of hyperlipemia.
    MOSER HW, EMERSON K.
    J Clin Invest; 1955 Aug; 34(8):1286-96. PubMed ID: 13242661
    [No Abstract] [Full Text] [Related]

  • 40. Lipid disorders and cardiovascular risks in nephrology.
    Dairou F.
    Nephrol Dial Transplant; 1998 Aug; 13 Suppl 4():30-3. PubMed ID: 9614662
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.